Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Jaap J. Zwaginga, Bronno van der Holt, Peter A. te Boekhorst, Bart J. Biemond, Mark-David Levin, Rene van der Griend, Anneke Brand, Sonja Zweegman, Hans F. M. Pruijt, Vera M. J. Novotny, Art Vreugdenhil, Marco R. de Groot, Okke de Weerdt, Elisabeth C. M. van Pampus, Tanja M. van Maanen-Lamme, Shulamiet Wittebol, Martin R. Schipperus, Matthijs H. Silbermann, Peter C. Huijgens, Marleen LutenRene Hollestein, Jan A. C. Brakenhoff, Jolanda G. Schrama, Fransje A. A. Valster, Gerjo A. Velders, Harry R. Koene

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E90-E92
JournalHaematologica-the Hematology Journal
Volume100
Issue number3
DOIs
Publication statusPublished - Mar 2015

Keywords

  • immune thrombocytopenia
  • rituximab
  • splenectomy delaying
  • early response
  • open label phase II

Cite this